Whitefort Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arbutus Biopharma
ABUS
|
+$10.3M |
| 2 |
NextNav
NN
|
+$8.07M |
| 3 |
CEE
Central and Eastern Europe Fund
CEE
|
+$128K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MYOV
Myovant Sciences Ltd.
MYOV
|
+$27M |
| 2 |
Roivant Sciences
ROIV
|
+$4.73M |
| 3 |
Genworth Financial
GNW
|
+$1.5M |
| 4 |
Tenet Healthcare
THC
|
+$1.42M |
| 5 |
DS
Drive Shack Inc.
DS
|
+$764K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 34.44% |
| 2 | Healthcare | 32.42% |
| 3 | Financials | 10.83% |
| 4 | Technology | 7.54% |
| 5 | Materials | 1.66% |
Similar funds
Whitefort Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Whitefort Capital Management held 21 positions worth $108M, down 16% from $129M the previous quarter. Its ten largest holdings account for 96% of the portfolio.
Whitefort Capital Management withdrew a net $20.5M in Q1 2023, closing 5 positions and reducing 3 holdings. Its most notable exit was Myovant Sciences Ltd., an estimated $27M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 34% of assets, up from 26% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Whitefort Capital Management added an estimated $10.3M to Arbutus Biopharma.
- Whitefort Capital Management added most to Arbutus Biopharma in Q1 2023, an estimated $10.3M increase.
- Whitefort Capital Management's biggest Q1 2023 reduction was Roivant Sciences, cutting an estimated $4.73M.
- Whitefort Capital Management fully exited Myovant Sciences Ltd. in Q1 2023, selling an estimated $27M.
- Whitefort Capital Management's ten largest holdings make up 96% of its $108M portfolio in Q1 2023.
- Whitefort Capital Management opened 0 new positions and closed 5 in Q1 2023.
- Whitefort Capital Management's portfolio value fell 16% quarter-over-quarter to $108M.
Based on Whitefort Capital Management's 13F filing for Q1 2023, filed 12 May 2023.